Clone:
REA780
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Alternative names:
B1, Bp35, Ly-44, MS4A1, CVID5, LEU-16, MS4A2, S7

Specifications for CD20 antibodies

Overview

REA780 recognizes the human CD20 antigen, a non-glycosylated transmembrane protein of 33–37 kDa that is expressed on B lineage cells from the pre–B cell stage to the B cell lymphoblast stage. The antigen is further expressed on most malignant B cells. CD20 is not found on early B cell progenitors or plasma cells. Oligomers of CD20 form a Ca
2+
channel and might function in the regulation of local responses during B cell activation.
Additional information: Clone REA780 displays negligible binding to Fc receptors.

Alternative names

B1, Bp35, Ly-44, MS4A1, CVID5, LEU-16, MS4A2, S7

Detailed product information

Technical specifications

CloneREA780
Isotyperecombinant human IgG1
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD20
Alternative names of antigenB1, Bp35, Ly-44, MS4A1, CVID5, LEU-16, MS4A2, S7
Molecular mass of antigen [kDa]33
Distribution of antigenB cells, dendritic cells, lymphocytes, cancer stem cells

Resources for CD20 antibodies

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD20 antibodies

Publications

  1. Lamprecht, B. et al. (2008) Aberrant expression of the Tʜ2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112(8): 3339-3347
  2. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
  3. Maxwell, S. A. et al. (2009) 14-3-3zeta J. Biol. Chem. 284(33): 22379-22389
  4. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
  5. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
  6. Countouriotis, T. B. et al. (2002) Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 20(3): 215-229
  7. Polyak et al. (2002) CD20 Workshop Panel report. In: Leucocyte typing VII, Oxford University Press.
  8. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
  9. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition
  10. Wood BL et al. (2007) 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin. Cytom. 72: 14-22